1 |
Compton DR, Hudzik TJ. Neurochemistry of abuse liability assessment and primary behavioral correlates. In: Carrie G. Markgraf, Thomas J. Hudzik, David R. Compton, Editors. Nonclinical assessment of abuse potential for new pharmaceuticals. 1st ed. Cambridge, MA: Academic Press; 2015. p. 9-48. https://doi.org/10.1016/B978-0-12-420172-9.00002-3
|
2 |
Hansen SN, Tveden-Nyborg P, Lykkesfeldt J. Does vitamin C deficiency affect cognitive development and function? Nutrients. 2014;6(9):3818-3846. https://doi.org/10.3390/nu6093818
DOI
|
3 |
Seitz G, Gebhardt S, Beck JF, Bohm W, Lode HN, Niethammer D, et al. Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene expression in the human neuroblastoma cell line SK-N-SH. Neuroscience Letters. 1998;244(1):33-36. https://doi.org/10.1016/s0304-3940(98)00129-3
DOI
|
4 |
Yan J, Studer L, McKay RD. Ascorbic acid increases the yield of dopaminergic neurons derived from basic fibroblast growth factor expanded mesencephalic precursors. Journal of Neurochemistry. 2001;76(1):307-311. https://doi.org/10.1046/j.1471-4159.2001.00073.x
DOI
|
5 |
Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting alpha-synuclein as a therapy for parkinson's disease. Frontiers in Molecular Neuroscience. 2019;12:299. https://doi.org/10.3389/fnmol.2019.00299
DOI
|
6 |
Rani L, Sharma N, Singh S, Grewal AS. Therapeutic potential of vitamin c: an overview of various biological activities. International Journal of Pharmaceutical Quality Assurance. 2019;10(04):605-612. https://doi.org/10.25258/ijpqa.10.4.8
DOI
|
7 |
Marini AM, Lipsky RH, Schwartz JP, Kopin IJ. Accumulation of 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine in cultured cerebellar astrocytes. Journal of Neurochemistry. 1992;58(4):1250-1258. https://doi.org/10.1111/j.1471-4159.1992.tb11336.x
DOI
|
8 |
Watanabe Y, Himeda T, Araki T. Mechanisms of MPTP toxicity and their implications for therapy of parkinson's disease. Medical Science Monitor. 2005;11(1):RA17-23.
|
9 |
Andersen JK, Chinta S. Parkinson's disease and aging. In: Sierra F, Kohanski R, editors. Advances in geroscience. 1st ed. Basel: Springer; 2016. P.229-255. https://doi.org/10.1007/978-3-319-23246-1.
|
10 |
Oudemans-van Straaten HM, Spoelstra-de Man AM, de Waard MC. Vitamin C revisited. Critical Care. 2014;18(4):460. https://doi.org/10.1186/s13054-014-0460-x
DOI
|
11 |
Sun H, Zu Y. A highlight of recent advances in aptamer technology and its application. Molecules. 2015;20(7):11959-11980. https://doi.org/10.3390/molecules200711959
DOI
|
12 |
Song MK, Lee JH, Kim J, Kim JH, Hwang S, Kim YS, et al. Neuroprotective effect of NXP031 in the MPTP-induced Parkinson's disease model. Neuroscience Letters. 2021;740:135425. https://doi.org/10.1016/j.neulet.2020.135425
DOI
|
13 |
Munoz-Manchado AB, Villadiego J, Romo-Madero S, Suarez-Luna N, Bermejo-Navas A, Rodriguez-Gomez JA, et al. Chronic and progressive parkinson's disease MPTP model in adult and aged mice. Journal of Neurochemistry. 2016;136(2):373-387. https://doi.org/10.1111/jnc.13409
DOI
|
14 |
Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979-980. https://doi.org/1126/science.6823561
DOI
|
15 |
Tanner CM, Langston JW. Do environmental toxins cause Parkinson's disease? A critical review. Neurology. 1990;40(10 Suppl 3):S17-S30.
|
16 |
Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. Aging Cell. 2019;18(6):e13031. https://doi.org/10.1111/acel.13031
DOI
|
17 |
Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42(6):1075-1081. https://doi.org/10.1161/01.HYP.0000100443.09293.4F.
DOI
|
18 |
Hwang O. Role of oxidative stress in Parkinson's disease. Experimental Neurobiology. 2013;22(1):11-17. https://doi.org/10.5607/en.2013.22.1.11
DOI
|
19 |
Das S, Basu A. Inflammation: a new candidate in modulating adult neurogenesis. Journal of Neuroscience Research. 2008;86(6):1199-1208. http://doi:10.1002/jnr.21585
DOI
|
20 |
Wang X, Michaelis EK. Selective neuronal vulnerability to oxidative stress in the brain. Frontiers in Aging Neuroscience. 2010;2:12. https://doi.org/10.3389/fnagi.2010.00012
DOI
|
21 |
Mallach A, Weinert M, Arthur J, Gveric D, Tierney TS, Alavian KN. Post mortem examination of parkinson's disease brains suggests decline in mitochondrial biomass, reversed by deep brain stimulation of subthalamic nucleus. FASEB Journal. 2019;33(6):6957-6961. https://doi.org/10.1096/fj.201802628r
DOI
|
22 |
Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. British Journal of Pharmacology. 2011;164(4):1357-1391. https://doi.org/10.1111/j.1476-5381.2011.01426.x
DOI
|
23 |
Radhakrishnan DM, Goyal V. Parkinson's disease: a review. Neurology India. 2018;66(Suppl):S26-S35. https://doi.org/10.4103/0028-3886.226451.
DOI
|
24 |
Santos Garcia D, Labandeira Guerra C, Yanez Bana R, Cimas Hernando MI, Cabo Lopez I, Paz Gonalez JM, et al. Safinamide improves non-motor symptoms burden in parkinson's disease: an open-label prospective study. Brain Sciences. 2021;11(3):316. https://doi.org/10.3390/brainsci11030316.
DOI
|
25 |
Lee JE, Choi JK, Lim HS, Kim JH, Cho JH, Kim GS, et al. The prevalence and incidence of parkinson's disease in South Korea: a 10-year nationwide population: Based Study. Journal of the Korean Neurological Association. 2017;35(4):191-198. https://doi.org/10.17340/jkna.2017.4.1
DOI
|
26 |
Hallett M. Parkinson's disease tremor: pathophysiology. Parkinsonism Related Disorders. 2012;18 Suppl 1:S85-S86. https://doi.org/10.1016/s1353-8020(11)70027-x
DOI
|
27 |
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nature Reviews Disease Primers. 2017;3:17013. https://doi.org/10.1038/nrdp.2017.13
DOI
|
28 |
Choi S, Han J, Kim JH, Kim AR, Kim SH, Lee W, et al. Advances in dermatology using DNA aptamer "Aptamin C" innovation: oxidative stress prevention and effect maximization of vitamin C through antioxidation. Journal of Cosmetic Dermatology. 2020;19(4):970-976. https://doi.org/10.1111/jocd.13081
DOI
|
29 |
Bornstein SR, Yoshida-Hiroi M, Sotiriou S, Levine M, Hartwig HG, Nussbaum RL, et al. Impaired adrenal catecholamine system function in mice with deficiency of the ascorbic acid transporter (SVCT2). FASEB Journal. 2003;17(13):1928-1930. https://doi.org/10.1096/fj.02-1167fje
DOI
|
30 |
Djuric G, Markovic V, Pekmezovic T, Tomic A, Kresojevic N, Kostic V, et al. Risk factors for levodopa-induced dyskinesia in parkinson's disease patients. Vojnosanitetski Pregled. 2017;74(10):921-926. https://doi.org/10.2298/VSP150723264D
DOI
|
31 |
Lyons KE, Pahwa R. Diagnosis and initiation of treatment in parkinson's disease. The International Journal of Neuroscience. 2011;121 Suppl 2:27-36. https://doi.org/10.3109/00207454.2011.620197
DOI
|
32 |
Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in parkinson's disease: mechanisms of action. Drug Discovery Today. 2016;21(5):802-818. https://doi.org/10.1016/j.drudis.2016.01.013
DOI
|
33 |
Jang SE, Qiu L, Chan LL, Tan EK, Zeng L. Current status of stem cell-derived therapies for parkinson's disease: from cell assessment and imaging modalities to clinical trials. Frontiers in Neuroscience. 2020;14:558532. https://doi.org/10.3389/fnins.2020.558532
DOI
|
34 |
Dawson TM, Ko HS, Dawson VL. Genetic animal models of parkinson's disease. Neuron. 2010;66(5):646-661. https://doi.org/10.1016/j.neuron.2010.04.034
DOI
|
35 |
Desole MS, Miele M, Esposito G, Fresu LG, Migheli R, Zangani D, et al. Neuronal antioxidant system and MPTP-induced oxidative stress in the striatum and brain stem of the rat. Pharmacology, Biochemistry, and Behavior. 1995;51(4):581-592. https://doi.org/10.1016/0091-3057(94)00401-4
DOI
|
36 |
Glotfelty EJ, Olson L, Karlsson TE, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for parkinson's disease. Expert Opinion on Investigational Drugs. 2020;29(6):595-602. https://doi.org/10.1080/13543784.2020.1764534.
DOI
|
37 |
Grieco M, Giorgi A, Gentile MC, d'Erme M, Morano S, Maras B, Filardi T. Glucagon-like peptide-1: a focus on neurodegenerative diseases. Frontiers in Neuroscience. 2019;13:1112. https://doi.org/10.3389/fnins.2019.01112
DOI
|
38 |
Hantikainen E, Trolle Lagerros Y, Ye W, Serafini M, Adami HO, Bellocco R, et al. Dietary antioxidants and the risk of parkinson disease: The Swedish National March Cohort. Neurology. 2021;96(6):e895-e903. https://doi.org/10.1212/WNL.0000000000011373
DOI
|
39 |
Choi S, Hwang Y, Kim T, Kim JH. Effects of oxidative stress prevention using DNA aptamer (Aptamin C®) in keratinocyte. Highlights on Medicine and Medical Science. 2021;17:9-16. https://doi.org/10.9734/bpi/hmms/v17/2795F
DOI
|
40 |
Mustapha M, Mat Taib CN. MPTP-induced mouse model of Parkinson's disease: a romising direction of therapeutic strategies. Bosnian Journal of Basic Medical Sciences. 2021;21(4):422-433. https://doi.org/10.17305/bjbms.2020.5181
DOI
|
41 |
Rice ME. Ascorbate regulation and its neuroprotective role in the brain. Trends in Neurosciencens. 2000;23(5):209-216. https://doi.org/10.1016/s0166-2236(99)01543-x
DOI
|
42 |
Smeyne M, Goloubeva O, Smeyne RJ. Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia. Glia. 2001;34(2):73-80.
DOI
|
43 |
Acuna AI, Esparza M, Kramm C, Beltran FA, Parra AV, Cepeda C, et al. A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington's disease in mice. Nature Communications. 2013;4:2917. https://doi.org/10.1038/ncomms3917.
DOI
|
44 |
Harrison FE, May JM. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radical Biology & Medicine. 2009;46(6):719-730. https://doi.org/10.1016/j.freeradbiomed.2008.12.018
DOI
|
45 |
Badanjak K, Fixemer S, Smajic S, Skupin A, Grunewald A. The contribution of microglia to neuroinflammation in prkinson's disease. International Journal of Molecular Sciences. 2021;22(9):4676. https://doi.org/10.3390/ijms22094676
DOI
|
46 |
Bhaduri B, Abhilash PL, Alladi PA. Baseline striatal and nigral interneuronal protein levels in two distinct mice strains differ in accordance with their MPTP susceptibility. Journal of Chemical Neuroanatomy. 2018;91:46-54. https://doi.org/10.1016/j.jchemneu.2018.04.005
DOI
|
47 |
Liebetanz D, Baier PC, Paulus W, Meuer K, Bahr M, Weishaupt JH. A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease. Experimental Neurology. 2007;205(1):207-213. https://doi.org/10.1016/j.expneurol.2007.01.030
DOI
|